A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

NCT01787383 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: Ingenol mebutate gel 0.05 %
DRUG: Ingenol mebutate gel 0.015 %

Sponsor

LEO Pharma